Show simple item record

dc.contributor.authorMcinnes, I
dc.contributor.authorBehrens, F
dc.contributor.authorMease, PJ
dc.contributor.authorKavanaugh, A
dc.contributor.authorRitchlin, CT
dc.contributor.authorNash, P
dc.contributor.authorGratacos-Masmitja, J
dc.contributor.authorGoupille, P
dc.contributor.authorKorotaeva, T
dc.contributor.authorGottlieb, AB
dc.contributor.authorMartin, R
dc.contributor.authorDing, K
dc.contributor.authorPellet, P
dc.contributor.authorMpofu, S
dc.contributor.authorPricop, L
dc.date.accessioned2020-11-18T00:14:48Z
dc.date.available2020-11-18T00:14:48Z
dc.date.issued2020
dc.identifier.issn0003-4967
dc.identifier.urihttp://hdl.handle.net/10072/399397
dc.description.abstractBackground: Secukinumab (SEC), an interleukin-17A inhibitor, has demonstrated improvements on multiple domains of psoriatic arthritis (PsA).1 Adalimumab (ADA), a TNF inhibitor, is widely used as a first–line biologic in PsA. Objectives: To report efficacy and safety outcomes from the head-to-head EXCEED trial (NCT02745080) that compares SEC vs. ADA as first–line biologic monotherapy through 52-weeks (wks), with a musculoskeletal primary endpoint in pts with active PsA. Methods: Head-to-head, phase-3b, randomised, double-blind trial: biologic naïve active PsA pts were randomised to receive SEC 300mg subcutaneous at baseline, Wk1-4, and then every 4wks (q4w) until Wk48 or ADA 40mg subcutaneous at baseline and then q2w until Wk50. The primary endpoint was superiority of SEC vs. ADA on ACR20 response at Wk52. Binary and continuous variables were analysed using logistic-regression model and MMRM, respectively. Safety analysis included patients who received ≥1 dose of study-drug. Results: 853 pts were randomised to receive SEC (n=426) or ADA (n=427). Baseline demographics and disease characteristics were comparable between treatment-groups except higher proportion of female pts and pts without enthesitis in the SEC group. ACR20 response at Wk52 for SEC vs. ADA were 67·4% vs. 61·5%, respectively (p=0·0719) (Figure). Higher clinical responses were observed with SEC vs. ADA for a range of musculoskeletal, skin, and higher-hurdle outcomes (Table). A higher retention rate was observed for SEC (85.7%) vs. ADA (76.3%). Safety profiles of SEC and ADA were consistent with previous reports.2,3 Conclusion: Results suggest that SEC is at least as efficacious as ADA on musculoskeletal endpoints whilst providing higher responses on skin endpoints, and is associated with a higher retention rate. No new safety signals were reported.
dc.languageEnglish
dc.publisherBMJ Publishing Group
dc.publisher.urihttps://ard.bmj.com/content/79/Suppl_1/142
dc.relation.ispartofconferencenameAnnual European Congress of Rheumatology (EULAR)
dc.relation.ispartofconferencetitleAnnals of the Rheumatic Diseases
dc.relation.ispartofdatefrom2020-06-03
dc.relation.ispartofpagefrom142
dc.relation.ispartofpageto143
dc.relation.ispartofissueSuppl 1
dc.relation.ispartofvolume79
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3204
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsRheumatology
dc.titleSecukinumab versus adalimumab head-to-head comparison in biologic-naive patients with active psoriatic arthritis through 52-weeks (exceed): a randomised, double-blind, phase-3B study
dc.typeConference output
dc.type.descriptionE3 - Conferences (Extract Paper)
dcterms.bibliographicCitationMcinnes, I; Behrens, F; Mease, PJ; Kavanaugh, A; Ritchlin, CT; Nash, P; Gratacos-Masmitja, J; Goupille, P; Korotaeva, T; Gottlieb, AB; Martin, R; Ding, K; Pellet, P; Mpofu, S; Pricop, L, Secukinumab versus adalimumab head-to-head comparison in biologic-naive patients with active psoriatic arthritis through 52-weeks (exceed): a randomised, double-blind, phase-3B study, Annals of the Rheumatic Diseases, 2020, 79, pp. 142-143
dc.date.updated2020-11-18T00:10:00Z
gro.hasfulltextNo Full Text
gro.griffith.authorNash, Peter


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record